At Novonesis, we believe solutions rooted in biology are key to tackling the challenges our world faces. Enzymes, functional proteins and microorganisms are our planet's tiniest, yet mightiest agents of change. When we leverage their power with science, we create biosolutions that transform the way we all produce, consume and live. Today, we are 10,000 people worldwide whose expertise spans more than 30 different industries. All around the world our biosolutions already create value for thousands of customers and benefit the planet. Our solutions enable feeding and fueling the world more sustainably, from healthy and sustainable nutrition to biofuel. Biosolutions also reduce the use of fossil-based resources, chemicals, energy and water. And this is just the beginning. The potential is almost endless. The time for biosolutions is now. And by working closely with our partners and customers, we will continue to challenge conventional thinking and transform business with biology. Together, we will create the change our world needs. Let’s better our world with biology.

Falls of Neuse Management LLC (FNMLLC) is an industry-leading and employee-owned company engaged in the sale and distribution of welding supplies and automotive industrial coatings. Operations are based in multiple locations throughout the United States. FNMLLC is owned by two companies: American Welding & Gas, Inc. (AWG) and National Coatings & Supplies, Inc. (NCS). We provide management support services for both of these companies from our corporate headquarters in Raleigh, NC.

UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. As one of the top 5 agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. With a presence in more than 130 countries and more than 10,000 colleagues globally, we reach more than 90% of the world’s food basket. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com.

Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma also has a full service contract development and manufacturing organizations (CDMO) servicing clients worldwide: Mayne Contract Services is based in Salisbury, SA, Australia Here are some key facts about our company: • 400+ staff • A$500m+ market cap • A$400m+ in revenue (FY22) • A product portfolio of 90+ marketed products globally The Company's corporate values are: • Empowerment – encouraging everyone to take initiative, enabling growth and achievement. • Passion – showing pride, enthusiasm and dedication in everything we do. • Creativity – delivering value and striving to connect new ideas with business realities. • Agility – operating with timeliness as well as mental, emotional and physical flexibility. • Integrity – maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. • Accountability – accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com. Our social media policy: https://bit.ly/3py3L1e Any communication you receive from Mayne Pharma will never come from a personal email domain or chat service such as "gmail" or "Google Chat". All official communication from Mayne Pharma will be received from our company email domain - @maynepharma.com.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Engineered to perform Qualicaps® is a global manufacturer of empty pharmaceutical capsules and pharmaceutical processing equipment. With more than 100 years of experience, Qualicaps is a leader in innovation in both Quali-G™ (gelatin) and Quali-V® (hypromellose) capsules, and offers a proprietary product line of pharmaceutical equipment, including capsule filling, band-sealing and inspection machinery. For more information visit www.qualicaps.com.

Based in Cary, NC, Atticus, LLC is an American-owned, bootstrapped and independently operated company. Atticus offers a broad and expanding portfolio of relevant, branded-generic pesticides for Agriculture and EcoCore markets. Driven by grassroots experience and an unwavering commitment to operational excellence, Atticus is an ally uniquely positioned to focus on long-term decisions that benefit retail distribution, the beautification of surroundings and the protection of essential infrastructure. Bringing products to market that complement agronomic and business needs is how Atticus helps retail distributors and end-users get the most out of their input requirements.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.

At Asymchem we are proud of the strides that we have made since our founding in 1999, providing R&D and one-stop production services to the world’s top pharmaceutical companies. Driving our success is our commitment to continual optimization and investing in the future. By improving the capabilities our partners need now, and maintaining the agility needed to support innovation, we’ve built a knowledge and experience base that we’re ready to share. Our solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem. Our 8 R&D and manufacturing sites are located in P.R. China and are regularly inspected by regulatory bodies such as the USFDA. Our expertise lies in developing and applying innovative technologies such as green chemistry for scaleup of technically complex API's, with the added advantage of in-house raw materials'​ manufacturing to control availability and lead-times. From initial development of a synthetic chemical process through to manufacturing, Asymchem’s proven team of experienced process and engineering teams has the knowledge to help our clients get things done. Asymchem's toolbox of capabilities include continuous flow reactions technologies, biocatalysis, asymmetric synthesis, HPAPI, cryogenic, catalytic hydrogenation, and others.

SBM Life Science offers innovative and responsible solutions and services to its customers and consumers for their plants, gardens, and living environments. Its range of products includes plant protection, soil and lawn seeds, plant food, and pest and mosquitoes control products to meet consumers’ needs: to Nourish, Beautify, Maintain, and Defend. SBM Life Science has several flagship brands in Europe: Protect Home®, Protect Garden® and Solabiol®, a pioneer in natural products in France since 2001. High-performing local brands complete the company’s offer in each European country, such as NutriOne®, Phostrogen® and Stroller®. In the United States, SBM Life Science Corp. is a key player in innovation in the lawn and garden market and stands with leading brands such as BioAdvanced® and Natria®, one of the leading brands in organic products. Recognized by its employees internationally, SBM Life Science was awarded Great Place To Work® certification in Europe in 2022, a recognition that echoes that obtained in the United States in 2021. In France, as part of the JardinPlus® 2022 Awards, SBM Life Science was elected Supplier of the Year by purchasing decision-makers from the retail sector. SBM Life Science, with 450 employees in 22 locations worldwide, is the Home & Garden subsidiary of the SBM Company. The group is positioned in four areas of activity: - agricultural crop protection, through the commercial entity CMPA - industrial production, with six plants (five in France and one in the United States) https://www.linkedin.com/company/sbm-formulation/ - aromatherapy, under the LCA brands https://www.linkedin.com/company/lca-aroma/ - Garden & Home, the group's main activity, with its subsidiaries SBM Life Science in Europe and the United States and the subsidiaries SPG and Or Brun in France. For more information: https://sbm-company.com/

NIOX is a hospitality company based out of 134 Avenue Franklin Roosevelt, Bruxelles, Belgium.